This article is for medical information and pre-consultation reference only. It does not replace diagnosis, prescription, or individualized medical advice. Availability, indications, and regulatory status may change over time and should be confirmed through qualified professionals and official sources.

Obesity medications have become one of the fastest-growing areas in global pharmaceuticals. The most important players are Novo Nordisk and Eli Lilly.

Both companies have transformed obesity treatment through GLP-1 and related therapies.

Novo Nordisk built major products such as Ozempic and Wegovy. The success of Semaglutide helped make the company one of Europe’s most valuable firms.

Historically, Novo Nordisk helped establish the GLP-1 market and has strong global brand recognition.

Eli Lilly entered the obesity spotlight later, but Tirzepatide quickly changed the competitive landscape. Key products include Mounjaro and Zepbound.

Unlike traditional GLP-1 therapies, Tirzepatide targets both GLP-1 and GIP, contributing to stronger average weight-loss results in studies.

Novo Nordisk is advancing oral Wegovy, CagriSema, and next-generation GLP-1 combination therapies. Lilly is advancing Retatrutide and Orforglipron.

Retatrutide represents a triple-agonist approach, while Orforglipron represents the oral GLP-1 strategy.

In the coming years, competition may shift further toward oral obesity drugs. Many patients prefer to avoid long-term injections.

If oral therapies can balance efficacy, safety, and convenience, they may significantly expand the market.

There may not be a single winner. Novo Nordisk has first-mover advantage, strong brand recognition, and a large user base. Lilly has strong Tirzepatide performance, promising Retatrutide data, and a rich pipeline.

The final outcome will depend on next-generation drug development, oral product strategy, global supply capacity, and long-term clinical evidence.

• Which is better, Ozempic or Mounjaro? They have different mechanisms; treatment choice should be individualized.
• Which company developed Retatrutide? Eli Lilly.
• Who has the long-term advantage? It remains uncertain, but both companies are likely to remain major leaders.
• Will oral obesity drugs become mainstream? Possibly, depending on efficacy, safety, and approvals.

The obesity drug market has entered a two-leader era. Novo Nordisk has Wegovy and Ozempic, while Lilly has Zepbound, Mounjaro, Retatrutide, and Orforglipron.

This competition is pushing obesity treatment from single-target drugs to dual and triple agonists, and from injectable therapies toward oral options.